Sunovion Pharmaceuticals Inc.has entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to three approved medicines, Utibron Neohaler inhalation powder, Seebri Neohaler inhalation powder and Arcapta Neohaler, which are indicated for the long-term, maintenance of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). The agreement expands Sunovion’s COPD portfolio in the U.S., providing handheld and nebulized treatment options for...